Takeda Told By U.S. FDA To Add Warning To Actos Label
This article was originally published in PharmAsia News
Takeda Pharmaceutical took a major hit when the U.S. FDA said the company would have to warn prospective one-year users of the diabetes drug Actos (pioglitazone) that it could cause an increased risk of bladder cancer
You may also be interested in...
Companies are racing to co-develop coronavirus treatments before finalizing deal teams. These team-ups raise questions about what happens after the pandemic subsides.
Plaintiffs against the prestige, “clinical” skin-care company are targeting anti-aging claims on its Rose Stem Cell Bio-Repair line and statements about hyaluronic acid’s ultra-moisturizing capabilities, used to market its Water Drench range. PTR faces false advertising class actions in California and New York federal courts, and the former case appears to be headed for trial.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.